Ocumension Plans Board Refresh With New Independent Director After Wu’s Retirement

The latest update is out from Ocumension Therapeutics ( (HK:1477) ).

Ocumension Therapeutics announced that independent non-executive director Ting Yuk Anthony Wu will retire at the upcoming annual general meeting after more than five years of service, stepping down as chairman of the audit committee and as a member of the remuneration and nomination committees. The board emphasized there is no disagreement or issue related to his departure and stated that the retirement will not affect the company’s operations, while expressing gratitude for his contributions.

To fill the vacancy, the company plans to appoint Beibei Zhuang as an independent non-executive director, chairwoman of the audit committee, and member of the remuneration and nomination committees, subject to shareholder approval at the AGM. Zhuang brings over 15 years of auditing and financial services experience, and after assessing her qualifications and independence, the board expects her appointment and three-year term to strengthen Ocumension’s financial reporting, internal controls and compliance.

The most recent analyst rating on (HK:1477) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

More about Ocumension Therapeutics

Ocumension Therapeutics is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong that focuses on ophthalmic treatments, operating through a group structure in China and other markets. The company is governed by a board with independent non-executive directors who play key roles in audit, remuneration and nomination oversight to support its compliance and corporate governance framework.

Average Trading Volume: 1,075,333

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.73B

For a thorough assessment of 1477 stock, go to TipRanks’ Stock Analysis page.